“40. The Trust is governed by the Trust Board, which is comprised of Non-Executive and Executive Directors. The Trust Board aims to meet on a monthly basis. The Trust's focus upon patient well-being is confirmed on any analysis of the Trust's Board Minutes, amongst other documents, which overwhelmingly focus on clinical issues. Unlike businesses such as the Defendants, litigation with other parties will rarely form the focus of the discussions held between Board members. This is not to say that the claim against the Defendants is not important; it is. It is simply not the most important thing that the Trust does and does not occupy any significant amounts of discussion at Board level. 41. …The Claimants became aware as early as 2018 that the remediation of the catastrophic defects at NSECH would likely require decant (however undesirable the prospect of decant is). 42. Having resolved in early 2018 that some form of decant of NSECH will be required to enable the defects to be remediated, whilst continuing to operate the Hospital and provide the vital public services, the Board has not had to engage further and separately to this litigation with the minutiae of planning such a process. The principle that decant is required has never changed and there is little more to be said or discussed at Board level beyond the acknowledgement that it is now known that it needs to occur and that the precise form of decant will need to be “sorted out” through the litigation. It is clear also that the Defendants hold an ingrained belief and expectation that documents (such as board minutes) will discuss, in some detail, matters which are significant in the claim. Those assumptions are misplaced. Board meetings at Trust level will rarely, in my experience, discuss matters relevant to litigation in any great detail and that is particularly the case with regards to the question of decant. This is because, at a high level, the principle of decant is a straightforward one in that the Claimants have demonstrated that, because of the criticality and practicalities of delivering clinical care, they cannot reasonably remediate NSECH without patients being decanted to another facility.”
“45. Following the Claimants’ response to the Defendants’ first RFI, Mr Beasley continued to work for the Claimants and the small project group of clinicians, led by Andrea Stoker and Beth Godwin, to further understand and consider the decant scheme as initially set out in the Claimants’ response to the Defendants’ RFI. 46. In January 2021, at my firm’s request, Mr Beasley and the small project group of clinicians led by Andrea Stoker and Beth Godwin were finalising what decant scheme was workable in the clinical environment that exists at NSECH and should, therefore, be pleaded, supported by a statement of truth.”
“48. For context, the small project group of clinicians led by Andrea Stoker and Beth Godwin only met six times between February 2021 and the RFI being served on13 August 2021 . The purpose of those meetings was to deal specifically with responses to requests for further information issued by the Defendants and to finalise the decant scheme that was going to be included in the Claimants’ pleadings. The Claimants ultimately provided an amended decant scheme by way of an amended response to the Defendants’ first RFI on13 August 2021 .” 49. As I have now explained, all of these meetings were convened by my firm at our request to allow us to develop and plead the decant scheme that would be needed in our answers to the RFIs and our pleadings. I do not understand how it can be said that those meetings and any minutes or notes of them are not privileged.”